Akriderm SK ointment d / nar. approx. 0,05% + 3% tube 15g
Category
Psoriasis
Scope of the drug
Dermatology
Release form
Ointment
Manufacturer country
Russia
Package quantity, pcs
one
Release form, composition and packaging
Ointment for external use 0.05% + 3% translucent, from white to white with a yellowish tinge
the presence of a weak specific smell is allowed.
100 g
betamethasone dipropionate in terms of 100% substance 0.064 g,
- which is equivalent to betamethasone 0.05 g
salicylic acid in terms of 100% substance 3 g
liquid paraffin (liquid paraffin) - 10 g, petroleum jelly - up to 100 g.
15 g - aluminum tubes (1) - cardboard packs.
30 g - aluminum tubes (1) - cardboard packs.
pharmachologic effect
Combination of corticosteroids with an antiseptic agent with keratolytic action.
Indications for use
Ointment AkridermSK is used for the treatment of subacute and chronic dermatoses, sensitive to external corticosteroid therapy, accompanied by hyperkeratosis:
- psoriasis
- atopic dermatitis (neurodermatitis)
- lichen planus
- eczema
- dyshydratic dermatitis
- ichthyosis and ichthyosiform changes.
Contraindications for use
- hypersensitivity to any component of the drug
- tuberculosis of the skin
- viral skin infections
- vaccination
- perioral dermatitis
- rosacea (rosacea).
Dosage regimen
The drug AkridermSK is applied with a thin layer on the inflamed surface 2 times / day, lightly rubbing.
In milder cases, a single use is sufficient.
The duration of treatment is usually limited to 3 weeks.
If a long course of therapy is required, it is recommended to use the drug less often, for example, every other day.
In the treatment of chronic diseases under the constant supervision of a physician, treatment should be continued for some time after the disappearance of all symptoms in order to avoid recurrence of the disease.
The use of the drug in children under 12 years of age is carried out under the supervision of the attending physician.
Overdose
If AkridermSK ointment is applied to large surfaces of inflamed, and therefore more permeable skin, for a long period (more than 3 weeks), using an occlusive dressing, as well as with prolonged use in children, enhanced absorption of active components and the manifestation of systemic effects of betamethasone are not excluded and salicylic acid.
In case of overdose, the use of the drug should be discontinued and consult a doctor.
Side effect
Side effects can be both local (at the site of application) and systemic (a consequence of systemic absorption of active ingredients).
At the site of application, a burning sensation, itching, folliculitis, acne, striae, skin atrophy, depigmentation and hypertrichosis may develop.
Very rarely, with prolonged use on large surfaces of the skin, when using occlusive dressings, increased percutaneous absorption of the active components of the drug is possible, which can cause systemic side effects manifested in the form of symptoms of GCS overdose (growth retardation, reversible suppression of the ACTH system, Cushing's syndrome, benign increase intracranial pressure after the end of treatment, hyperglycemia, glycosuria, hypokalemia, increased blood pressure)
side effects caused by salicylates: pallor, fatigue, drowsiness, hyperventilation and tachypnea, nausea, vomiting, hearing impairment, confusion, etc.
In case of side effects, you should consult a doctor.
In the event of a secondary skin infection, adequate antifungal and antibiotic therapy should be used.
Do not use antifungal and antibacterial drugs yourself!
Consult your doctor!
Drug interactions
There were no clinically significant interactions with other drugs.
Application during pregnancy and lactation
The use of AkridermSK ointment in pregnant women tolerance
Name ENG
AKRIDERM SK
Clinical and pharmacological group
Drug with anti-inflammatory and keratolytic action for external use
ATX code
Betamethasone in combination with other drugs
Dosage
0.05% + 3% x 15g
Structure
1 g of ointment contains: active substances: betamethasone dipropionate 0.64 mg and salicylic acid 30 mg
auxiliary substances: petroleum jelly, liquid paraffin.
Indications
Local treatment of dermatoses, accompanied by hyperkeratosis: psoriasis, limited and diffuse neurodermatitis, lichen planus, eczema, dyshidrotic dermatitis, ichthyosis and ichthyosiform changes.
Storage conditions and periods
At a temperature of 15-25 degrees.
Expiration date: 3 years
INN / Active ingredient
salicylic acid, betamethasone
Contraindications
Hypersensitivity to any of the components of the drug, skin tuberculosis, skin manifestations of syphilis, chickenpox, herpes simplex, post-vaccination skin reactions, open wounds, lactation and children under 1 year of age
additionally for Akriderm: trophic ulcers of the leg, rosacea, acne vulgaris
additionally for the drug Akriderm GK: in the treatment of external otitis media perforation of the tympanic membrane
additionally for Akriderm SK: perioral dermatitis.
Specifications
Category
Psoriasis
Scope of the drug
Dermatology
Release form
Ointment
Manufacturer country
Russia
Package quantity, pcs
one
Minimum age from
1 year
Way of introduction
On the skin
Vacation conditions
Without recipe
Brand name
Akrikhin
The amount of the dosage form in the primary package
15 g
Primary packaging type
Tuba
Type of consumer packaging
Pack of cardboard
Anatomical and therapeutic characteristics
D07XC01 Betamethasone, in combination with other drugs
Dosage form
Ointment for external use
The target audience
Children
Expiration date in days
1095
Package weight, g
15
Mode of application
:
Outwardly.
Akriderm SK is applied with a thin layer on the affected skin area 2 times a day - in the morning and in the evening.
A different frequency of use can be established by a doctor, based on the severity of the disease.
In mild cases, it is sufficient to apply the ointment, as a rule, once a day
more severe lesions may require more frequent use.
Pharmaco-therapeutic group
:
Topical glucocorticosteroid + keratolytic agent
Dosage (volume) of the substance in the preparation
:
betamethasone dipropionate 0.064 g, which is equivalent to betamethasone 0.05 g, salicylic acid 3 g
Information on technical characteristics, delivery set, country of manufacture